1. Introduction

Tissue repair biologics are biological products and advanced therapeutic materials designed to restore, regenerate, reconstruct or replace damaged human tissues. They may be used in the treatment of burns, chronic wounds, bone defects, cartilage injuries, skin damage, nerve injuries and other conditions involving tissue degeneration.

Examples include:

Stem-cell-based tissue regeneration products.

Platelet-rich plasma (PRP) and other blood-derived preparations.

Tissue-engineered skin substitutes.

Collagen-based wound-healing products.

Biological scaffolds and extracellular matrix materials.

Cultured human cells and regenerative tissue products.

Gene-modified cells used for tissue repair.

In Morocco, clinical authorization of these products must be considered within the country's pharmaceutical, biomedical research, medical practice, human tissue protection and public-health frameworks.

The central legal issue is whether a tissue repair biologic can be administered to human patients only after satisfying the applicable requirements for product authorization, ethical approval, clinical research authorization, manufacturing quality, safety monitoring and informed consent.

An important distinction is that Morocco does not necessarily have a single, comprehensive statutory category equivalent to the European Union's Advanced Therapy Medicinal Products (ATMP) regime. Consequently, the legal classification of each product is important.

2. Legal Framework Governing Tissue Repair Biologics in Morocco

Several areas of Moroccan law may apply.

A. Law No. 17-04: Pharmaceutical and Medicinal Products Framework

Law No. 17-04, establishing the Code of Medicines and Pharmacy, is a central part of Morocco's pharmaceutical regulatory framework.

It regulates matters including:

Pharmaceutical products and medicinal preparations.

Marketing authorization.

Manufacturing and pharmaceutical quality.

Importation and distribution.

Pharmaceutical establishments.

Pharmacovigilance and product safety.

Regulatory supervision of medicinal products.

Where a tissue repair biologic falls within the legal definition of a medicinal product, the relevant pharmaceutical authorization requirements become important.

For example, a cultured-cell product intended to regenerate damaged skin may require medicinal-product assessment depending on its composition, manufacturing process, intended therapeutic purpose and legal classification.

A product cannot avoid pharmaceutical regulation merely because it is described commercially as a regenerative treatment, biological preparation or tissue-repair technology.

B. Law No. 28-13: Biomedical Research Involving Human Participants

Law No. 28-13 concerning the protection of persons participating in biomedical research provides an important legal framework for clinical investigations.

Its relevance includes:

Protection of research participants.

Informed consent.

Ethical assessment of research protocols.

Scientific justification for human experimentation.

Protection of vulnerable participants.

Compliance with research-related safeguards.

Responsibilities of research investigators and sponsors.

A clinical investigation involving a new tissue repair biologic must be assessed according to the applicable biomedical research requirements.

For example, a clinical study investigating cultured stem cells for the treatment of severe burns must consider participant protection, research ethics, the scientific validity of the protocol and the applicable administrative authorization.

Important distinction: Ethical approval and authorization to conduct biomedical research are not automatically equivalent to marketing authorization for the product.

C. Law No. 65-00: Compulsory Health Insurance Framework

Law No. 65-00 establishing the basic compulsory health insurance scheme is relevant to the broader question of healthcare access and reimbursement.

A tissue repair biologic may receive the necessary regulatory authorization without automatically becoming eligible for reimbursement.

Regulatory approval, clinical availability and insurance coverage are separate legal questions.

D. Law No. 09-08: Personal Data Protection

Law No. 09-08 concerning the protection of individuals with regard to the processing of personal data is particularly relevant when tissue repair research involves:

Genetic information.

Biological sample identification.

Patient medical records.

Stem-cell donor information.

Clinical trial databases.

Long-term monitoring of regenerative treatments.

Research institutions must consider applicable personal-data protection requirements, including the role of the National Commission for the Control of Personal Data Protection (CNDP).

E. Human Tissue and Organ Protection Rules

Human tissue research also raises questions concerning donation, procurement, storage, traceability and the use of human biological materials.

The relevant Moroccan legal framework includes legislation governing the donation and transplantation of human organs and tissues, including Law No. 16-98 and its implementing provisions.

The application of these rules depends on the nature of the material and whether the activity constitutes transplantation, tissue procurement, research or pharmaceutical manufacturing.

A donated tissue sample used to manufacture a therapeutic biologic raises different legal questions from a conventional pharmaceutical ingredient.

3. Special Regulatory Position of Cell-Based Tissue Repair Therapies

One of the most important developments in Moroccan regenerative medicine regulation occurred in June 2019.

The Moroccan Ministry of Health issued a circular restricting activities involving autologous cell therapy preparations.

According to the Ministry's official announcement dated 6 June 2019:

Collection, processing and administration of autologous cell therapy preparations for therapeutic or research purposes were restricted to approved public or private university hospital centres.

The relevant establishments had to receive Ministry approval.

The approval process involved consultation with the Advisory Council for Human Organ Transplantation.

The facilities and their preparation, preservation and therapeutic-indication procedures were subject to assessment.

Patient informed consent was required before collection and administration.

This is particularly significant for tissue repair biologics involving stem cells and other autologous cellular preparations.

sante.gov.ma+1

Practical legal consequence: A private clinic cannot assume that it may lawfully collect, manipulate and administer a patient's cells simply because the cells originate from that same patient.

The regulatory position depends on the type of cellular preparation, its intended purpose and the establishment's authorization.

Authorized institutional examples

The Ministry's official regulatory records identify specific establishments authorized for autologous haematopoietic stem-cell transplantation, including:

Hôpital Privé Marrakech — Ministerial Decision No. 1466-19 of 30 April 2019.

Clinique Ibn Rochd — Ministerial Decision No. 110-19 of 21 February 2019.

These decisions demonstrate that institutional approval is an important part of Morocco's regulatory approach to cellular therapies. They should not, however, be interpreted as blanket authorization for every type of stem-cell or tissue-engineering treatment.

sante.gov.ma

4. Clinical Authorization Requirements

Clinical authorization of tissue repair biologics involves several distinct legal stages.

A. Product classification

The first step is determining the legal nature of the proposed product.

A product's classification should be established before clinical use. A product combining cells and a scaffold may require assessment under more than one regulatory framework.

B. Scientific and preclinical evidence

Before human clinical investigation, the sponsor should establish a sufficient scientific basis for the proposed treatment.

Relevant evidence includes:

Cell identity and characterization.

Purity and biological composition.

Cell viability and stability.

Sterility and microbiological safety.

Tumorigenicity assessment where relevant.

Immunological compatibility.

Potential genetic abnormalities.

Reproducibility of the manufacturing process.

Evidence supporting the proposed therapeutic mechanism.

Appropriate animal or other preclinical studies.

For example, a company developing a cultured skin substitute for burn victims should demonstrate that the product can support tissue repair without introducing unacceptable infection, abnormal cell growth or immune-related risks.

C. Ethics committee approval

Biomedical research involving human participants must comply with Law No. 28-13 and its implementing framework, including Decree No. 2.20.326.

Ethical assessment should consider:

The scientific value of the research.

The proportionality of risks and expected benefits.

Participant selection.

Informed consent.

Protection of vulnerable patients.

Confidentiality.

Procedures for managing research-related injury.

Continuing safety oversight.

The Moroccan General Secretariat of Government lists Decree No. 2.20.326 among the implementing texts associated with Law No. 28-13.

SGG+1

D. Clinical research authorization

A sponsor proposing to investigate a new tissue repair biologic must establish compliance with the applicable authorization requirements for biomedical research.

A suitable submission will generally need to address:

Clinical trial protocol.

Investigational product description.

Manufacturing and quality information.

Preclinical safety data.

Investigator qualifications.

Research site suitability.

Participant information and consent documents.

Risk-management arrangements.

Insurance or compensation arrangements where legally required.

The relevant Ministry and competent authorities must determine the applicable authorization route.

Ethical approval alone should not be treated as permission to begin a clinical trial.

E. Manufacturing and Good Manufacturing Practice

Manufacturing quality is essential for cell-based and tissue-engineered products.

The manufacturer should establish appropriate controls for:

Donor and patient identification.

Collection and transportation.

Cell processing.

Contamination prevention.

Batch documentation.

Storage conditions.

Cryopreservation, where relevant.

Product release testing.

Distribution and traceability.

For an autologous product, the patient's original biological material must remain traceable throughout processing and administration.

A failure to maintain this chain of identity can result in administration of the wrong biological preparation, potentially causing serious injury.

F. Marketing authorization

Where the product qualifies as a medicinal product, Law No. 17-04 and the applicable implementing regulations become central.

The Moroccan regulatory framework includes Decree No. 2-14-841 concerning marketing authorization for medicines for human use.

The applicant must follow the appropriate regulatory procedure and demonstrate the necessary quality, safety and efficacy evidence.

A clinical-trial authorization is not equivalent to authorization to market a product commercially.

sante.gov.ma+2

5. Regulatory Authorities and Their Responsibilities

The Ministry's 2019 announcement expressly identifies the role of the Advisory Council in the approval of relevant cellular therapy establishments.

sante.gov.ma

6. Informed Consent and Patient Rights

Informed consent is a fundamental requirement in tissue repair biologics research.

Patients must receive understandable information about:

The experimental nature of the treatment.

The scientific purpose of the procedure.

Potential benefits and uncertainties.

Known and reasonably foreseeable risks.

Available alternative treatments.

The possibility of treatment failure.

The collection and storage of biological materials.

The use of personal and genetic information.

The right to withdraw from research, subject to applicable legal limitations.

Consent must be voluntary and based on adequate information.

A particularly important concern arises when a patient suffering from severe burns or a chronic wound is offered an experimental stem-cell procedure.

The patient's vulnerability must not be exploited through exaggerated claims that the treatment is guaranteed to regenerate tissue.

A signed consent form does not automatically protect a hospital or investigator from liability for negligence, unlawful research or inadequate disclosure.

7. Post-Authorization Monitoring and Pharmacovigilance

Authorization is not the end of regulatory responsibility.

Tissue repair biologics may produce delayed complications, particularly when living cells or genetically modified materials are involved.

Post-treatment monitoring should address:

Infection and contamination.

Immune reactions.

Abnormal tissue formation.

Tumor development.

Graft rejection.

Treatment failure.

Long-term tissue function.

Unexpected adverse events.

For products regulated as medicinal products, applicable pharmacovigilance obligations must also be considered.

For clinical investigations, sponsors and investigators must comply with the relevant safety-reporting and monitoring requirements.

The regulator may take appropriate corrective measures, including suspension of a research activity or product authorization, where the applicable legal conditions are met.

8. Legal Liability for Unauthorized Clinical Use

Unauthorized administration of tissue repair biologics can create several forms of legal liability.

A. Administrative liability

A healthcare establishment may face regulatory intervention if it conducts restricted cellular therapy activities without the required institutional approval.

Possible consequences include suspension of the activity, withdrawal of authorization or other administrative measures under applicable law.

B. Civil liability

A hospital, investigator or sponsor may become liable where a patient's injury results from negligence, inadequate safety procedures, defective preparation or breach of applicable legal duties.

C. Research sponsor liability

Article 34 of Law No. 28-13 is particularly important.

It provides for sponsor responsibility for damage affecting a research participant's health during or after biomedical research where a causal relationship with the research is established.

The sponsor must provide full compensation and maintain civil liability insurance covering the research, including the relevant investigators and other participants in the research activity.

The administration may suspend or withdraw research authorization where the sponsor fails to obtain or renew the required insurance.

Ma Loi

D. Professional liability

Doctors and other healthcare professionals may face professional or civil consequences for:

Administering unapproved treatments unlawfully.

Failing to obtain informed consent.

Misrepresenting experimental treatments as established therapies.

Ignoring contraindications.

Failing to monitor adverse events.

Violating professional standards.

E. Data protection liability

Improper collection, disclosure or processing of genetic and medical information may raise issues under Law No. 09-08 and the applicable CNDP requirements.

9. Important Case Laws and Legal Precedents

A distinction must be made between reported Moroccan judicial decisions, Moroccan administrative regulatory decisions and foreign comparative judgments.

There is a limited publicly identifiable body of Moroccan reported case law specifically concerning clinical authorization of tissue-engineered products or regenerative stem-cell biologics. It would therefore be inaccurate to invent Moroccan court judgments on this subject.

The following authorities provide relevant legal guidance.

Case 1: Moroccan administrative authorization decisions concerning stem-cell transplantation

Ministerial Decision No. 110-19, 21 February 2019

This decision authorized Clinique Ibn Rochd to conduct autologous haematopoietic stem-cell transplantation.

Ministerial Decision No. 1466-19, 30 April 2019

This decision authorized Hôpital Privé Marrakech to conduct the same type of transplantation.

Legal significance:

These decisions illustrate the importance of institutional authorization for specialized cellular treatment.

They also demonstrate that authorization is connected to the particular establishment and therapeutic activity concerned. Approval for haematopoietic stem-cell transplantation does not automatically authorize unrelated tissue-engineering procedures.

These are administrative decisions, not reported judicial precedents.

sante.gov.ma+1

Case 2: Brüstle v Greenpeace eV (2011)

Court of Justice of the European Union — Case C-34/10

The dispute concerned patentability of inventions involving human embryonic stem cells.

The European Court of Justice considered the meaning of the human embryo and the limits imposed by European patent law.

Legal significance for Morocco:

Although this judgment does not govern Moroccan clinical authorization, it offers comparative guidance concerning:

Ethical limitations on human biological materials.

The legal status of embryonic stem-cell research.

Public-policy restrictions on biotechnology.

The relationship between scientific innovation and human dignity.

It is particularly relevant when tissue repair research involves embryonic stem cells rather than adult or induced pluripotent stem cells.

Case 3: International Stem Cell Corporation v Comptroller General of Patents (2014)

Court of Justice of the European Union — Case C-364/13

The dispute concerned the patentability of inventions involving parthenogenetically activated human ova.

The Court examined whether the biological material could develop into a human being and how this affected the application of the European patent exclusion.

Legal significance:

The judgment illustrates why the biological characteristics of the material must be considered when determining the ethical and legal status of a regenerative technology.

For Morocco, it provides comparative guidance when assessing research involving unusual sources of human cells.

It does not establish a Moroccan clinical approval rule.

Case 4: United States v. Regenerative Sciences, LLC (2014)

United States Court of Appeals for the District of Columbia Circuit — 741 F.3d 1314

This dispute involved a clinic's use of cultured autologous cells for treatment.

The court considered the application of federal drug regulation to the clinic's cell-processing activities.

Legal significance:

The decision illustrates an important regulatory principle: the fact that cells originate from a patient does not necessarily remove a processed cellular product from medicinal-product regulation.

This principle is relevant when evaluating Moroccan autologous cell preparations under Law No. 17-04 and the 2019 Ministry restrictions.

The American judgment is comparative, not binding in Morocco.

Case 5: S.H. and Others v. Austria (2011)

European Court of Human Rights — Application No. 57813/00

The case concerned restrictions on assisted reproductive technologies and the relationship between reproductive science, individual rights and state regulation.

Legal significance:

Although not a tissue repair case, it provides broader comparative guidance on the balancing of medical innovation, individual autonomy and public-interest regulation.

It may be useful when discussing the ethical and constitutional dimensions of emerging biotechnology in Morocco.

10. Particularly Important Moroccan Statutory Authority: Article 24 of Law No. 28-13

Article 24 deserves special attention because it expressly addresses the location and institutional conditions of biomedical research.

It provides that biomedical research must be conducted in qualifying healthcare establishments or approved research sites.

More importantly, it specifically restricts research involving industrially manufactured medicinal products for:

Cell therapy.

Gene therapy.

Xenogeneic cell therapy.

Stable blood derivatives.

Such research is restricted to public healthcare establishments or qualifying research sites associated with university hospital centres, subject to the statutory conditions.

It also requires suitable human, material and technical resources and administrative approval of research sites.

This provision is particularly significant for tissue repair biologics because it directly addresses the clinical research environment for certain advanced cellular products.

Ma Loi

Example: If a pharmaceutical company develops an industrially manufactured stem-cell product intended to regenerate damaged cartilage, Article 24 becomes especially important when determining where the clinical investigation can lawfully take place.

The product's precise classification and intended use must still be examined.

11. Recent Regulatory Developments and Legal Evolution (2026)

Morocco's biomedical research framework has continued to develop.

An important recent development is Decree No. 223 of 30 April 2026, published in May 2026, which amends and supplements Decree No. 2.20.326 implementing Law No. 28-13.

This development is relevant because clinical authorization procedures must be examined against the updated implementing framework rather than relying exclusively on the original 2021 text.

Eastlaws+1

Another development is the Moroccan Agency for Medicines and Health Products (AMMPS) publication, dated 9 May 2026, of guidance concerning the import and export of human medicines.

The guidance addresses specific import authorizations, including certain clinical-trial situations, and emphasizes traceability and regulatory compliance. This may be relevant when tissue repair biologics or investigational medicinal products are imported for authorized research.

AMMPS

12. Practical Example: Clinical Authorization of a Stem-Cell Skin Repair Product

Consider a Moroccan biotechnology company developing a cultured autologous skin-cell preparation for patients suffering from severe burns.

The legal process would involve the following stages:

Product classification

Determine whether the preparation is a medicinal product, a tissue transplantation preparation or another regulated health product.

Biological material collection

Establish lawful collection, donor or patient consent, identification and traceability.

Manufacturing validation

Demonstrate sterility, identity, purity, viability and appropriate quality controls.

Institutional approval

Obtain the relevant establishment authorization, particularly where the 2019 cellular therapy restrictions apply.

Ethical approval

Submit the clinical research protocol for the applicable ethics review.

Clinical research authorization

Obtain the necessary administrative authorization under Law No. 28-13 and its implementing regulations.

Clinical investigation

Conduct the study according to the approved protocol and participant-protection requirements.

Safety monitoring

Record adverse events and comply with reporting, insurance and follow-up obligations.

Marketing authorization

If the product is a medicinal product, pursue the applicable marketing authorization before ordinary commercial distribution.

A company cannot lawfully bypass the relevant requirements by describing the treatment as an experimental regenerative procedure or by claiming that the cells are autologous.

13. Major Legal Challenges

Morocco faces several regulatory challenges in this area.

14. Recommendations for Strengthening Moroccan Law

Morocco could strengthen its regulatory framework through the following measures:

1. Specific tissue-engineered product legislation: Introduce clearer statutory classifications for engineered tissues, cell therapies and combined biological products.

2. Advanced therapy authorization procedures: Establish dedicated clinical authorization pathways for regenerative medicinal products.

3. Standardized manufacturing requirements: Develop specialized quality standards for cell processing, tissue engineering and biological scaffolds.

4. National clinical research registry: Improve transparency concerning authorized regenerative medicine trials.

5. Long-term patient monitoring: Require appropriate follow-up for therapies involving living cells and genetically modified materials.

6. Cross-border traceability: Strengthen controls governing the import, export, storage and transfer of human biological materials.

7. Patient compensation: Ensure effective implementation of research insurance and compensation requirements.

8. Regulatory coordination: Improve coordination between AMMPS, the Ministry of Health, research ethics committees and transplantation authorities.

9. Advertising supervision: Prevent unsubstantiated claims that experimental tissue repair treatments provide guaranteed regeneration.

10. Judicial guidance: Encourage the development of accessible judicial decisions concerning experimental therapies, informed consent and biological-product liability.

15. Conclusion

Regulation of tissue repair biologics clinical authorization in Morocco involves an interconnected framework of pharmaceutical law, biomedical research legislation, human tissue protection, institutional authorization, patient consent and clinical safety.

Three legal instruments are particularly important:

Law No. 17-04: Pharmaceutical regulation and medicinal-product authorization.

Law No. 28-13: Protection of persons participating in biomedical research.

Law No. 16-98: Donation, procurement and transplantation of human organs and tissues.

Article 24 of Law No. 28-13 is especially important because it establishes specific institutional restrictions for certain cell-therapy and gene-therapy investigations. The Ministry's June 2019 circular further demonstrates Morocco's approach to controlling autologous cellular therapies.

The central legal principle is that scientific innovation cannot replace regulatory authorization. A tissue repair biologic must satisfy the requirements applicable to its classification, clinical investigation, manufacturing, institutional use and eventual commercialization.

Ultimately, Morocco's regulatory system seeks to balance regenerative medicine innovation with patient safety, human dignity, scientific integrity and public-health protection.

16. Important Legal References and Research Sources

Primary research sources:

Moroccan Ministry of Health – Biomedical Research and Medical Practice Regulations.

Moroccan Ministry of Health – Medicines and Pharmacy Regulations.

Ministry announcement on restrictions on cellular therapies (6 June 2019).

General Secretariat of Government – Consolidated Regulatory Texts.

Decree No. 223 of 2026 – Amendment to biomedical research regulations.

Article 34 of Law No. 28-13 – Sponsor Liability.

Article 24 of Law No. 28-13 – Biomedical Research Sites and Cell Therapy.

Academic qualification: The cited Moroccan administrative decisions and foreign judgments provide regulatory and comparative guidance, not a body of directly applicable Moroccan judicial precedents on tissue repair biologics. The current consolidated Arabic legislation and official implementing texts should be checked before relying on a particular authorization pathway.